Simplex Trading’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Simplex Trading’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,444	Closed	-$2K	–	10388
2023 Q1	$2K	Buy	+1,444	New	+$1.95K	﹤0.01%	8605
2022 Q2	–	Sell	-2,280	Closed	-$5.63K	–	11524
2022 Q1	$6K	Buy	2,280 +1,773	+350%	+$5.58K	﹤0.01%	9368
2021 Q4	$2K	Buy	+507	New	+$3.17K	﹤0.01%	10107
2021 Q1	–	Sell	-1,316	Closed	-$35.9K	–	10378
2020 Q4	$40K	Sell	1,316 -506	-28%	-$12.8K	﹤0.01%	6413
2020 Q3	$37K	Buy	1,822 +1,437	+373%	+$25.2K	﹤0.01%	5901
2020 Q2	$5K	Buy	385 +165	+75%	+$1.9K	﹤0.01%	7016
2020 Q1	$1K	Buy	+220	New	+$2.69K	﹤0.01%	7443

Simplex Trading's TCRR Position: Q2 2023 in Review

Simplex Trading sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 1,444 shares — an estimated $2K sold.

Simplex Trading first reported a position in TCRR in Q1 2020 and held it in 7 quarters. The position peaked at $40K in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Simplex Trading reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Simplex Trading sold 1,444 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $2K.
Simplex Trading first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2020 and held it in 7 quarters.
Simplex Trading's TCR2 Therapeutics Inc. Common Stock position peaked at $40K in Q4 2020.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.